3-fluoro-N-methyl-4-morpholinoaniline | 1187929-61-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 3-fluoro-N-methyl-4-morpholinoaniline
• 英文别名: (3-Fluoro-4-morpholin-4-yl-phenyl)-methyl-amine；3-fluoro-N-methyl-4-morpholin-4-ylaniline
• CAS: 1187929-61-8
• 化学式: C₁₁H₁₅FN₂O
• 分子量: 210.251
• InChiKey: GANOIVNLPVHGHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-(2-氟-4-硝基苯基)吗啉 在 甲醇 、 rhodium(III) chloride hydrate 、 potassium tert-butylate 作用下， 反应 48.0h， 生成 3-fluoro-N-methyl-4-morpholinoaniline
  参考文献：
  名称：

  简单的RuCl3催化的胺的N-甲基化和使用甲醇的硝基芳烃的转移加氢

  摘要：

  甲醇是潜在的氢源和C 1合成子，在化学合成和能源技术中都有有趣的应用。在有机合成中有效利用这种简单的醇具有至关重要的意义，并引起了科学兴趣。本文中，我们报道了一种清洁且具有成本竞争力的方法，该方法使用甲醇作为C 1合成子和H 2源，通过使用相对便宜的RuCl 3 .xH 2 O作为无配体催化剂，对胺进行选择性N-甲基化。这种易于获得的催化剂可耐受各种包含缺电子基团和供电子基团的胺，并使它们转化为相应的N甲基化产品，产率中等至优异。此外，很少有市售的药剂（例如文拉法辛和丙咪嗪）是通过后期功能化从容易获得的原料化学品中成功合成的，从而突出了这种先进的N-甲基化反应的合成价值。在该平台上，我们还尝试与选定的硝基芳烃进行串联反应，以在H 2下使用MeOH将它们转化为相应的N甲基化胺。无条件的条件包括硝基芳烃到苯胺的转移氢化以及制备的药物分子（例如苯佐卡因和丁苯本）以及关键的医药中间体。我们进一步使

  DOI：

  10.1002/cctc.202001937

文献信息

• Commercial Pd/C-Catalyzed <i>N</i>-Methylation of Nitroarenes and Amines Using Methanol as Both C1 and H₂ Source
  作者：Vishakha Goyal、Jyoti Gahtori、Anand Narani、Piyush Gupta、Ankur Bordoloi、Kishore Natte

  DOI：10.1021/acs.joc.9b02141

  日期：2019.12.6

  Herein, we report commercially available carbon-supported-palladium (Pd/C)-catalyzed N-methylation of nitroarenes and amines using MeOH as both a C1 and a H-2 source. This transformation proceeds with high atom-economy and in an environmentally friendly way via borrowing hydrogen mechanism. A total of >30 structurally diverse N-methylamines, including bioactive compounds, were selectively synthesized with isolated yields of up to 95%. Furthermore, selective N-methylation and deuteration of nimesulide, a nonsteroidal anti-inflammatory drug, were realized through the late-stage functionalization.
• SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY
  申请人：The Global Alliance for TB Drug Development, Inc.

  公开号：US20200148651A1

  公开（公告）日：2020-05-14

  The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
• NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME
  申请人：MEDICINAL BIOCONVERGENCE RESEARCH CENTER

  公开号：US20220204497A1

  公开（公告）日：2022-06-30

  The present invention pertains to a novel compound having anticancer activity, and a method for producing same, and more specifically, to a novel compound that exhibits excellent anticancer activity by inhibiting the expression of AIMP2-DX2, and a method for producing same. The compound represented by chemical formula 1 according to the present invention is highly effective in inhibiting the expression of AIMP2-DX2, and thus can be very advantageously used for the development of agents for treating various diseases, in particular cancer, caused by AIMP2-DX2.